RIBOLARIS

BIG 21-02

Partager cette publication

Neoadjuvant and adjuvant RIBOciclib + endocrine therapy for cLinicAlly high-RISk ER+/HER2-negative breast cancer

This is a study being conducted in multiple hospitals around the world involving men and women with a specific type of breast cancer that can still be treated through surgery. The study focuses on cancers that are positive for hormone receptors, negative for  HER2, have a high level of marker ki67, and are considered moderately to more aggressive (grade 2 or 3), and in an early but significant stage (stage II).

The aim of the study is to see if a non-chemotherapy treatment is safe and effective over the long term for patients who respond well to a combination of two drugs, ribociclib and letrozole, before surgery.

This study aims to evaluate whether chemotherapy could be avoided for initial high-risk clinicopathological breast cancer patients that are converted to low genomic risk assessed by Risk of Recurrence-low (ROR-low) at 6 months of letrozole – ribociclib neoadjuvant treatment by continuing with this treatment in adjuvant setting.

Aim: 530 patients in the whole clinical trial, from 33 study locations in France and 15 in Spain.

Coordinating group: SOLTI (sponsor)

Pharma partner: Novartis Pharma AG

There are two participating BIG Groups

55 study locations are involved in Spain and other EU countries.

Funding: Novartis Pharma AG

More To Explore

RIBOLARIS

RIBOLARIS BIG 21-02 Share This Post Neoadjuvant and adjuvant RIBOciclib + endocrine therapy for cLinicAlly high-RISk ER+/HER2-negative breast cancer What This is a study being

Read More

OPTIMA

OPTIMA BIG 22-02 Share This Post Optimal personalised treatment of early breast cancer using multi-parameter analysis What Optimal personalised treatment of early breast cancer using

Read More